Photon-Counting CT Improves Lung Cancer Detection, Reduces Kidney Injury Risk

Lung cancer screening and diagnosis may be poised for a significant leap forward, with new research indicating that photon-counting computed tomography (PCCT) offers distinct advantages over conventional CT scans. A prospective study published in Radiology suggests that PCCT not only reduces radiation exposure and contrast media use but also improves the detection of malignant features and boosts diagnostic confidence. The findings, released on March 23, 2026, could lead to earlier and more accurate diagnoses, potentially improving outcomes for individuals with lung cancer.

Enhanced Detection and Reduced Risk

The study, led by Songwei Yue, MMed, chief physician and professor at The First Affiliated Hospital of Zhengzhou University in China, compared PCCT to standard-dose energy-integrating detector (EID) CT in 100 adults with lung lesions matched for key characteristics. Researchers found that PCCT significantly reduced radiation exposure by 66.34% (effective dose of 1.36 mSv vs. 4.04 mSv) and iodine exposure (20.62 mg vs. 28.08 mg). Perhaps even more critically, adverse reactions were significantly less frequent in the PCCT group (2% vs. 9%), and contrast-induced acute kidney injury was also less common (1% vs. 7%).

These benefits stem from PCCT’s ability to capture and quantify individual photons, providing higher resolution images with reduced noise. As previously demonstrated, this technology allows for the detection of subtle changes in lung tissue that might be missed by conventional CT. In this latest study, PCCT detected more features of heterogeneous enhancement and malignancy-related imaging features compared to EID CT, particularly with a 0.4 mm section thickness.

Image Quality Across Body Mass Index

The study also investigated how PCCT performance varied across different body mass index (BMI) categories. Even as PCCT consistently delivered high scores for image quality in underweight and normal-weight individuals, a 1 mm section reconstruction proved more suitable for overweight patients. This suggests that PCCT protocols can be tailored to individual patient characteristics to optimize image quality and diagnostic accuracy. Specifically, for lesions 3 cm or less, a 0.4 mm section thickness with PCCT yielded higher structural scores, while a 1 mm reconstruction was preferable for larger tumors.

What Does This Signify for Patients?

The implications of these findings are substantial. Lung cancer is often diagnosed at a late stage, when treatment options are limited. Improved detection rates, coupled with reduced risk of adverse effects from contrast agents, could lead to earlier intervention and better patient outcomes. The lower radiation dose associated with PCCT is also a significant advantage, particularly for individuals who require repeated scans for monitoring purposes. However, it’s important to note that this study focused on a specific population and further research is needed to confirm these findings in larger, more diverse cohorts.

Understanding the Technology: Photon-Counting CT vs. Conventional CT

Conventional CT scans measure the total energy of X-rays that pass through the body. This provides information about tissue density, but it can be limited in its ability to differentiate between subtle differences in tissue composition. PCCT, directly measures the energy of each individual photon. This allows for a more precise and detailed image, with improved contrast resolution and reduced noise. The technology also enables lower radiation doses and reduced contrast media use, as less energy is needed to generate a high-quality image.

Diagnostic Confidence and the Role of Radiologists

The study highlighted a significant increase in diagnostic confidence among radiologists using PCCT, particularly when assessing enhancement-related malignant features. This increased confidence is likely due to the improved image quality and the ability to visualize subtle details that might be missed on conventional CT scans. The researchers emphasized that while PCCT is a powerful tool, it still requires skilled radiologists to interpret the images accurately. The study utilized a 5-point Likert scale for assessment, relying on the expertise of thoracic radiologists to evaluate image quality and lesion characteristics.

The Future of Lung Cancer Imaging

Yue and his colleagues believe that PCCT has the potential to replace conventional CT as the standard of care for lung cancer screening and diagnosis. As of March 23, 2026, the technology is still relatively new and not yet widely available, but its adoption is expected to increase as more hospitals and imaging centers invest in PCCT scanners. Further research is ongoing to optimize PCCT protocols and explore its potential applications in other areas of medical imaging. The development of artificial intelligence (AI) algorithms to assist with image analysis and interpretation is also expected to play a key role in maximizing the benefits of PCCT.

Looking ahead, the integration of PCCT into clinical practice will likely involve ongoing evaluation of its cost-effectiveness and impact on patient outcomes. Continued monitoring of adverse event rates and refinement of imaging protocols will be essential to ensure the safe and effective use of this promising new technology. The potential for personalized imaging strategies, tailored to individual patient characteristics, also represents an exciting area for future research.

For individuals concerned about lung cancer risk, it’s important to discuss screening options with a qualified healthcare professional. The Centers for Disease Control and Prevention (CDC) provides comprehensive information on lung cancer screening guidelines and risk factors.